E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10048439 |
E.1.2 | Term | Fibromyalgia |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate the superiority of terguride 3 mg/d over placebo in the 12 week treatment of fibromyalgia associated pain on the visual analogue scale (VAS) called "Schmerzskala" from Mundipharma. |
|
E.2.2 | Secondary objectives of the trial |
To investigate the safety and tolerability of terguride in patients suffering from fibromyalgia. To assess the influence of terguride on: · Fibromyalgia Impact Questionnaire (FIQ-G), · Tender Point Score (TPS), · Hamilton Depression Scale
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients (m or f) are eligible for the study when they fulfil the following criteria: ·Diagnosis of fibromyalgia according to ACR criteria (1990) [Wolfe et al. 1990] ·Pain score ³50 mm on the patient pain VAS (100 mm) ·Tender point Score (TPS) ³ 11 ·Age range from 18 to 60 y (inclusive) ·Body Mass Index (BMI): 18.9 < BMI < 30.0 ·A written informed consent to participate in this study signed by the subject prior to initiation of any study specific procedure ·Treatment as outpatients
|
|
E.4 | Principal exclusion criteria |
A patient fulfilling the following exclusion criteria must not enter the study: · known sensitivity to study drug · suffering from relevant liver (limit for GOT and GPT: < 3-fold of upper limit of NR), kidney (limit for serum creatinine: < 1.5 mg/dL), cardiovascular (i.e. heart attack or cerebrovascular disease) or pulmonary disease (i.e. asthma or COPD) · suffering from pituitary tumor representing extrasellar expansion · suffering from peptic ulcers or having a history of it · suffering from Raynaud syndrome or having a history of it · suffering from psychosis or having a history of it · suffering from a systolic blood pressure ³140 mm Hg and a diastolic pressure ³ 90 mm Hg. (Criteria in accordance with the 7th report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure (NIH Publication # 04-5230 (2004)) · suffering from Encephalomyelitis disseminata · suffering from chronic inflammatory diseases · evidence or history of drug or alcohol abuse · mental impairment limiting the ability to comply with study requirements · receiving therapy with agents known or likely to interact with study drug or disease: - Antidepressants or SSRIs are not allowed from 6 weeks before V(-1) throughout the entire study. However, patients with substantial therapeutic benefit from such compounds should not be discontinued for study participation. - Antiepileptics, Anxiolytics, Muscle relaxants or Hypnotics have to be discontinued at least 10 elimination half lives of the respective drug before V(-1); for details see section 9.4.7, · participation in any clinical study or donation of blood in the period from 60 days prior to study initiation until end of study . Additionally, women with child bearing potential must be excluded if: · They have not used reliable contraception in the cycle before the study. According to CPMP/ICH/286/95 (modification) highly effective methods of birth control (defined by a failure rate < 1% per year) include the consistent and correct use of implants, injectables combined oral contraceptives, selected intrauterine devices (IUD), sexual abstinence or vasectomised partner The subject has to agree to continue using such highly reliable contraception during the entire study period and the cycle after the study · They are pregnant or lactating. (A negative pregnancy test must be provided for all female subjects with child bearing potential at screening and on Day 0)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy variable is the pain intensity given by the patient on the VAS (0 100 mm) called "Schmerzskala" from Mundipharma. The absolute and relative (%) change from baseline (V0) to V12 will be calculated for each patient. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial is defined as the last visit of the last subject undergoing the trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 9 |